BACKGROUND and AIM: IL28B genotype predicts response to pegylated-interferon (peg-IFN)-based
IL28B GENOTYPE IS NOT USEFUL FOR PREDICTING TREATMENT OUTCOME IN ASIAN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED

INTRODUCTION:
Chronic infection with the hepatitis B virus (HBV) remains a significant global health issue with more than 350 million individuals infected with the virus worldwide 1 , the majority in the Asia Pacific region 2 . Chronic HBV infection (CHB) is associated with significant morbidity and mortality related to the complications of cirrhosis and hepatocellular carcinoma 3, 4 . Sustained virological suppression following treatment with either oral nucleos(t)ide analogues (NAs) or pegylated-interferon-α (peg-IFN) has been shown to reduce these complications [5] [6] [7] . Peg-IFN therapy offers the benefit of fixed treatment course, with a standard duration of 48 weeks. However, among HBeAg-positive patients, the HBeAg seroconversion rate approximates only 35% in most studies and treatment may be associated with considerable morbidity. In HBeAg-negative CHB, rates of on-treatment response are reasonable, but the long-term sustained virological response is low, approximately 10%. HBsAg seroconversion occurs more commonly than with NA therapy, but may take many years to achieve.
Pre-treatment factors that have been associated with response to peg-IFN treatment include HBV genotype, HBeAg status, high baseline ALT levels and low baseline HBV DNA levels [8] [9] [10] . Unfortunately, for the individual patient it is difficult to predict treatment response and there is a need to identify more accurate biomarkers of peg-IFN treatment response.
IL28B polymorphisms (rs12979860 and rs8099917) have been associated with IFN response in the setting of chronic hepatitis C virus infection (CHC) [11] [12] [13] . 
HBV serology and DNA levels
HBsAg and anti-HBs, and HBeAg and anti-HBe were tested using enzyme immunoassay kits (Vidas Ultra, bioMerieux, Marcy l'Etoile, France and AxSYM, Abbott, Abbott Park, IL, USA respectively) according to the manufacturer's instructions. Prior to July 2008, HBV DNA levels were determined using the Versant 3.0 assay (Bayer HealthCare, Tarrytown, NY, USA) with a lower limit of quantification (LLQ) of 2.55 log 10 IU/mL and an upper limit of quantification (ULQ) of7.25 log 10 IU/mL. After July 2008, HBV DNA levels were determined using the Abbott m2000 (Abbott Labs, Abbott Park, IL, USA), LLQ 1.18 log 10 IU/mL and ULQ9.00 log 10 IU/mL. For patients whose baseline HBV DNA level was >ULQ and for whom baseline serum was available (n=18/34), serial dilutions were performed to obtain an accurate quantitative HBV DNA level using COBAS® AmpliPrep/COBAS® TaqMan® HBV Test, v2.0
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(Roche Molecular Diagnostics, Pleasanton, CA, USA) (see supplementary table 1 for a summary of HBV DNA testing).
IL28B genotype testing
Host DNA was extracted from 200 microlitres of stored serum using the QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). IL28B genotype (rs12979860) testing was performed on the extracted DNA via realtime PCR using the TaqMan allelic discrimination kit (Applied Biosciences, Foster City, CA, USA).
Rs12979860 is biallelic (C and T) with three possible genotypes: CC genotype, predicting "good response" to peg-IFN and ribavirin therapy in CHC, and CT and TT genotypes predicting "poor response".
Outcomes
The primary analysis focussed on the association between IL28B genotype (rs12979860) and treatment efficacy, defined for HBeAg-positive patients as HBeAg seroconversion (undetectable HBeAg and detectable anti-HBe in serum) with HBV DNA <3.30 log 10 IU/mL (<2,000 IU/mL) at 24 weeks after completing therapy. In HBeAg-negative patients, as HBV DNA <3.30 log 10 IU/mL at 24 weeks posttreatment. The association between IL28B genotype and HBeAg loss, HBsAg loss, normalisation of ALT at 24 weeks post-treatment (defined as ALT <19 IU/mL in females and <30 IU/mL in males), >2 log 10 IU/mL reduction in HBV DNA levels during therapy (previously identified as a predictor of treatment response in both HBeAg-positive and HBeAg-negative CHB 18, 19 ), HBV DNA <2.60 log 10 IU/mL (<400 IU/mL) at 24 weeks post treatment in HBeAg negative patients and maintenance of the primary endpoint at 48 weeks post cessation of therapy and at the end of follow-up were also evaluated.
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Statistical analysis
STATA, version 11.1 (StataCorp, College Station, TX, USA) was used to perform statistical analysis.
Mann-Whitney-U test was used to analyse continuous data, presented as median with interquartile range, and Fischer's exact and Chi squared tests were used to compare categorical data.
RESULTS: Patient demographics and baseline characteristics
A total of 118 CHB patients treated with peg-IFN monotherapy were identified at both centre. IL28B
genotype was determined in 96 (81%) of these patients, and were included in this study. Patient characteristics are summarized in Table 1 . In brief, 63% were HBeAg-positive and 38% were HBeAgnegative. The majority were of Asian ethnicity (88% (Figure 1a , Table 2 ). The only pretreatment factors associated with achieving a response were baseline HBV DNA <7 log 10 IU/mL (p=0.005), lower median HBV DNA levels (6.64 vs 7.25 log 10 IU/mL, p=0.021) and female sex (50% vs 20%, p=0.03). On-treatment predictors of the primary endpoint were >2 log 10 IU/mL reduction in HBV DNA level at treatment weeks 12 and 24 (p=0.006 for both associations) ( Table 2 ). There was no difference in the frequency of these on-treatment milestones comparing CC and non-CC patients (data not shown). The primary endpoint was achieved in 48% of patients with a baseline HBV DNA level <7 log 10 IU/mL, but only 14% achieved this primary endpoint if their baseline HBV DNA levels was ≥7 log 10 IU/mL. The primary outcome was met by 75% of patients achieving a >2 log 10 IU/mL HBV DNA reduction at treatment week 12 compared with only 29% of those with <2 log 10 IU/mL HBV DNA reduction at treatment week 12. 
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Secondary outcomes
The overall rate of HBeAg loss at week 24 post-treatment was 47% (28/60 an overall long-term response rate of 39%. This was not influenced by IL28B genotype (Figure 1b ).
Secondary outcomes:
Sixteen patients (44%) achieved a serum HBV DNA level <2.60 log 10 IU/mL at 24 weeks post-therapy. 
IL28B
HBsAg seroclearance
A total of five patients (5%) from the entire cohort achieved HBsAg loss, four were HBeAg-positive and three carried the CC IL28B genotype. The median time to HBsAg loss was 11.1 months (8.8-18.4 months).
DISCUSSION
In our largely Asian cohort of CHB patients treated with peg-IFN monotherapy, the majority (>80%) of patients carried the CC IL28B genotype for rs12979860), which has previously been associated with the overall treatment outcomes were consistent with previously published studies 21, 22 .
In CHC, the rs12979860 IL28B polymorphism has been shown to have the highest predictive value for treatment response in CHC, higher than rs8099917 . IL28B genotype (rs8099917) was not associated with
HBeAg-seroconversion or HBeAg-seroconversion plus HBV DNA <20,000 IU/mL (4.30 log 10 IU/mL). In addition, natural history studies have evaluated the association between IL28B genotype and the outcome of HBV infection. In contrast to HCV, no association between IL28B genotype and spontaneous clearance of HBV has been demonstrated [26] [27] [28] . Existing data are therefore conflicting.
Comparison between studies is limited by heterogeneity of patient populations, as well as treatment regimens. One particular difference between our cohort and the studies that suggested an association between IL28B genotype and CHB treatment outcome relates to the ethnic distribution of the populations. Ethnicity is strongly linked to both HBV genotype and host IL28B genotype distribution.
The patients in our study were almost exclusively Asian, and our study is the first to focus on this population. Although HBV genotype was not routinely tested in all patients for this study, previous studies from our group have shown that Asian patients are predominantly infected with HBV 
